Your Genes Are Not Your Cancer Destiny: How Epigenetics and Nutrition Influence Cancer Risk

written by Debbie Dolan Sweeney, BCHN, FDNP, ONC

“Cancer runs in my family.”

This statement often carries a sense of inevitability, as if a cancer diagnosis were simply waiting in our genetic code. While family history matters, emerging research in epigenetics and nutrigenomics reveals a more empowering truth: the majority of cancers are not predetermined by genetics alone. In fact, only 5-10% of cancers are attributable to inherited genetic mutations, while 90-95% involve environmental and lifestyle factors that modify gene expression.¹

Understanding the difference between what you inherit and what you control is crucial for cancer prevention and as a complementary approach during cancer treatment.

What You Inherit: Cancer Susceptibility Genes
Certain inherited genetic mutations do significantly increase cancer risk. The BRCA1 and BRCA2 mutations, for example, can increase lifetime breast cancer risk to 55-72% and ovarian cancer risk to 39-44%.² Lynch syndrome mutations in DNA mismatch repair genes substantially elevate colorectal and other cancer risks.³ TP53 mutations in Li-Fraumeni syndrome create vulnerability to multiple cancer types.⁴

Beyond these high-penetrance mutations, numerous SNPs influence cancer risk more subtly. Variants in genes controlling detoxification (GSTT1, GSTM1), DNA repair (XRCC1), inflammation (TNF-alpha), and nutrient metabolism (VDR, MTHFR) all modulate individual cancer susceptibility.⁵ These genetic variants don’t cause cancer directly—they create a terrain that may be more or less receptive to cancer development depending on environmental inputs.
However, even individuals with high-risk genetic mutations can dramatically influence whether those genes lead to cancer through epigenetic and metabolic interventions.⁶

What You Control: The Epigenetic Landscape of Cancer

Cancer is fundamentally a disease of altered gene expression. While genetic mutations can initiate cancer, epigenetic modifications—changes in how genes are expressed without altering DNA sequence—drive cancer progression and determine the tumor microenvironment.⁷
During cancer development, tumor suppressor genes become abnormally “silenced” through DNA methylation, while oncogenes become aberrantly “activated.”⁸ The remarkable insight is that these epigenetic changes are potentially reversible through targeted nutrition and lifestyle interventions.⁹

Your daily choices create the epigenetic environment in which cancer either thrives or struggles to survive:

Diet-induced epigenetic changes: Specific nutrients and phytochemicals directly modify DNA methylation patterns and histone modifications. Folate, B vitamins, and compounds from cruciferous vegetables, green tea, turmeric, and berries have demonstrated epigenetic effects that can reactivate silenced tumor suppressor genes.^10,11

Metabolic reprogramming: Cancer cells exhibit the “Warburg effect”—preferential use of glucose fermentation even in oxygen-rich environments.¹² By modifying macronutrient ratios and timing (such as through therapeutic ketogenic approaches or fasting-mimicking diets), you can create a metabolic environment less favorable to cancer cell proliferation while supporting normal cell function.¹³

Inflammatory modulation: Chronic inflammation creates an epigenetic environment that promotes cancer initiation and progression.¹⁴ Anti-inflammatory dietary patterns rich in omega-3 fatty acids, polyphenols, and fiber can modify gene expression patterns related to inflammatory pathways.¹⁵

Nutrigenomics in Cancer Prevention and Treatment
Nutrigenomics offers precision approaches to cancer care by matching specific nutrients to individual genetic profiles and cancer biology. This represents a shift from generic dietary recommendations to personalized nutrition strategies.

Sulforaphane and NRF2 Activation
Sulforaphane from broccoli sprouts activates the NRF2 pathway, inducing expression of over 200 genes involved in antioxidant defense and detoxification.¹⁶ This compound has shown particular promise in prostate, breast, and colon cancer by inducing cancer cell apoptosis while protecting normal cells from oxidative damage.¹⁷

Vitamin D and Gene Regulation
Vitamin D functions as a hormone that regulates expression of over 1,000 genes, including those controlling cell proliferation, differentiation, and apoptosis.¹⁸ Adequate vitamin D status influences cancer risk across multiple cancer types, with mechanisms including immune modulation and direct anti-proliferative effects on cancer cells.¹⁹

Omega-3 Fatty Acids and Inflammation
DHA and EPA modify expression of genes controlling inflammation, angiogenesis, and metastasis.²⁰ These fatty acids can sensitize cancer cells to chemotherapy while protecting normal tissues from treatment-related damage.²¹

Polyphenols and Cell Signaling
Compounds like EGCG from green tea, curcumin from turmeric, and resveratrol from grapes modulate multiple signaling pathways involved in cancer progression, including NF-κB, PI3K/AKT, and MAPK pathways.²² These phytochemicals can induce epigenetic changes that restore normal gene expression patterns in cancer cells.²³

The Terrain-Over-Tumor Approach in Oncology
In integrative metabolic oncology, we focus on optimizing the body’s internal environment—the terrain—to create conditions inhospitable to cancer while supporting the efficacy of conventional treatments. This approach recognizes that cancer develops not just from genetic mutations, but from a permissive metabolic and immune environment.²⁴

Core Terrain Optimization Strategies:

Metabolic flexibility: Supporting the body’s ability to efficiently use ketones and fatty acids for fuel while limiting glucose availability to cancer cells through strategic carbohydrate timing and quality.²⁵
Insulin sensitivity: Maintaining healthy insulin signaling, as hyperinsulinemia and insulin resistance create growth signals that promote cancer cell proliferation and survival.²⁶

Mitochondrial health: Supporting normal mitochondrial function in healthy cells while exploiting cancer cells’ reliance on dysfunctional mitochondrial metabolism.²⁷
Immune optimization: Providing nutrients that support natural killer cell function, T-cell activity, and immune surveillance while reducing immunosuppressive factors in the tumor microenvironment.²⁸

Circadian rhythm alignment: Respecting natural light-dark cycles and meal timing to optimize melatonin production, which has significant anti-cancer effects and modulates genes involved in circadian rhythm regulation.²⁹
Toxic burden reduction: Minimizing exposure to environmental carcinogens and endocrine disruptors that create epigenetic changes favoring cancer development.³⁰

Practical Application: Complementing Standard Cancer Care

It’s essential to emphasize that this nutrigenomic and epigenetic approach complements, not replaces, standard oncology care. Surgery, chemotherapy, radiation, and immunotherapy remain crucial tools. However, optimizing the metabolic and epigenetic terrain can:

• Enhance treatment efficacy by making cancer cells more vulnerable to conventional therapies
• Protect normal cells from treatment-related damage
• Support immune system function during and after treatment
• Address cancer stem cells that often resist conventional treatment
• Reduce recurrence risk by creating an inhospitable environment for residual cancer cells³¹

Evidence-Based Interventions:

For patients with BRCA mutations: Despite high genetic risk, enhanced vegetable intake, particularly cruciferous vegetables high in sulforaphane, has demonstrated protective effects. Adequate folate status supports proper DNA methylation patterns. Maintaining healthy weight and avoiding alcohol further reduces epigenetic cancer risk.³²

During active treatment: Fasting-mimicking approaches before chemotherapy (differential stress resistance) can protect normal cells while sensitizing cancer cells to treatment. Specific nutrients like glutamine may protect gut integrity during treatment, while others like high-dose vitamin C may enhance chemotherapy efficacy.^33,34

For prevention in high-risk individuals: Mediterranean dietary patterns rich in olive oil, fatty fish, colorful vegetables, and minimal processed foods create an epigenetic and metabolic environment associated with significantly reduced cancer incidence.³⁵

Your Daily Choices Matter Most

While genetic testing can identify susceptibilities requiring enhanced vigilance, the most powerful interventions lie in daily choices that modify gene expression. Every meal, every stress response, every hour of sleep, and every movement pattern sends epigenetic signals to your cells.

The terrain-over-tumor philosophy recognizes that cancer develops in bodies that have lost metabolic flexibility, immune surveillance, and proper gene regulation. By optimizing these fundamental processes through evidence-based nutrition and lifestyle interventions, you’re not just preventing cancer—you’re creating a cellular environment where cancer cannot easily thrive.
Your genetic code may load the gun, but your lifestyle choices determine whether that trigger ever gets pulled. Even more importantly, for those already diagnosed with cancer, these same principles can help create a terrain that supports conventional treatment success and long-term survival.

This is not alternative medicine—it’s integrative, evidence-based oncology that respects both the power of modern cancer treatment and the profound influence of metabolic optimization on cancer biology.

References

1. Anand P, Kunnumakkara AB, Sundaram C, et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res. 2008;25(9):2097-2116.
2. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402-2416.
3. Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP. Milestones of Lynch syndrome: 1895-2015. Nat Rev Cancer. 2015;15(3):181-194.
4. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250(4985):1233-1238.
5. Coughlin SS, Hall IJ. A review of genetic polymorphisms and prostate cancer risk. Ann Epidemiol. 2002;12(3):182-196.
6. King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643-646.
7. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683-692.
8. Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358(11):1148-1159.
9. Hardy TM, Tollefsbol TO. Epigenetic diet: impact on the epigenome and cancer. Epigenomics. 2011;3(4):503-518.
10. Fang M, Chen D, Yang CS. Dietary polyphenols may affect DNA methylation. J Nutr. 2007;137(1 Suppl):223S-228S.
11. Meeran SM, Ahmed A, Tollefsbol TO. Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin Epigenetics. 2010;1(3-4):101-116.
12. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-314.
13. Weber DD, Aminazdeh-Gohari S, Kofler B. Ketogenic diet in cancer therapy. Aging (Albany NY). 2018;10(2):164-165.
14. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-899.
15. Calder PC, Ahluwalia N, Brouns F, et al. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br J Nutr. 2011;106 Suppl 3:S5-78.
16. Kensler TW, Egner PA, Agyeman AS, et al. Keap1-nrf2 signaling: a target for cancer prevention by sulforaphane. Top Curr Chem. 2013;329:163-177.
17. Traka M, Gasper AV, Melchini A, et al. Broccoli consumption interacts with GSTM1 to perturb oncogenic signalling pathways in the prostate. PLoS One. 2008;3(7):e2568.
18. Hossein-nezhad A, Spira A, Holick MF. Influence of vitamin D status and vitamin D3 supplementation on genome wide expression of white blood cells: a randomized double-blind clinical trial. PLoS One. 2013;8(3):e58725.
19. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014;14(5):342-357.
20. Gleissman H, Johnsen JI, Kogner P. Omega-3 fatty acids in cancer, the protectors of good and the killers of evil? Exp Cell Res. 2010;316(8):1365-1373.
21. Bougnoux P, Hajjaji N, Ferrasson MN, Giraudeau B, Couet C, Le Floch O. Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br J Cancer. 2009;101(12):1978-1985.
22. Teiten MH, Eifes S, Dicato M, Diederich M. Curcumin-the paradigm of a multi-target natural compound with applications in cancer prevention and treatment. Toxins (Basel). 2010;2(1):128-162.
23. Link A, Balaguer F, Goel A. Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem Pharmacol. 2010;80(12):1771-1792.
24. Winters N. The Metabolic Approach to Cancer: Integrating Deep Nutrition, the Ketogenic Diet, and Nontoxic Bio-Individualized Therapies. White River Junction, VT: Chelsea Green Publishing; 2017.
25. Klement RJ, Kämmerer U. Is there a role for carbohydrate restriction in the treatment and prevention of cancer? Nutr Metab (Lond). 2011;8:75.
26. Arcidiacono B, Iiritano S, Nocera A, et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res. 2012;2012:789174.
27. Wallace DC. Mitochondria and cancer. Nat Rev Cancer. 2012;12(10):685-698.
28. Gao Y, Li S, Wang Y, et al. Implications of immune cell metabolism for cancer immunotherapy. Cell Death Dis. 2018;9(2):126.
29. Blask DE, Dauchy RT, Sauer LA. Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine. 2005;27(2):179-188.
30. Baccarelli A, Bollati V. Epigenetics and environmental chemicals. Curr Opin Pediatr. 2009;21(2):243-251.
31. Goyal MM, Basak A. Lifestyle interventions in cancer. Asian Pac J Cancer Prev. 2012;13(9):4127-4138.
32. Kotsopoulos J, Olopado OI, Ghadirian P, et al. Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2005;7(5):R833-R843.
33. Lee C, Raffaghello L, Brandhorst S, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med. 2012;4(124):124ra27.
34. Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 2014;6(222):222ra18.
35. Schwingshackl L, Schwedhelm C, Galbete C, Hoffmann G. Adherence to Mediterranean diet and risk of cancer: an updated systematic review and meta-analysis. Nutrients. 2017;9(10):1063.